Stepan Company (SCL) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
2025 was a transformational year, marked by record safety performance, divestiture of two manufacturing plants, optimization of the global footprint, and the commissioning of the Pasadena, TX facility.
Despite macroeconomic and sector pressures, adjusted EBITDA grew 6% to $198.9 million, with organic volume up 2% year-over-year, driven by crop productivity, oil field, polymers, and specialty products.
Project Catalyst was launched to deliver $100 million in pre-tax savings over two years, focusing on footprint optimization, operational efficiency, and organizational effectiveness.
Positive free cash flow and improved net leverage ratio from 2.8x to 2.5x year-over-year.
Financial highlights
Full year reported net income was $46.9 million, down 7% year-over-year; adjusted net income was $41.7 million, down 17%.
Full year adjusted EBITDA rose 6% to $198.9 million; free cash flow was $25.4 million.
Q4 2025 adjusted net loss was $0.5 million; reported net income was $5 million, up 49% year-over-year due to asset sale gains and non-recurring items.
Q4 adjusted EBITDA was $33.8 million, down 3% year-over-year, mainly from lower surfactants income and higher raw material costs.
Net debt reduced by $32 million to $494 million; leverage ratio improved from 2.8x to 2.5x.
Outlook and guidance
Expect adjusted EBITDA growth and positive free cash flow in 2026, with H2 performance stronger due to lower raw material costs, Project Catalyst savings, and anticipated demand recovery.
$60 million of Project Catalyst savings expected in 2026, mostly realized in H2; inflation will offset some savings.
Q1 2026 impacted by historic weather, resulting in $6 million EBITDA loss, mainly in surfactants, with at least half expected to be recovered by year-end.
CapEx guidance for 2026 is $105–$115 million, reflecting a return to pre-pandemic base levels with some growth investments; effective tax rate expected to rise to 25–27% due to new US tax legislation.
Latest events from Stepan Company
- Net loss of $41.4M driven by restructuring, with adjusted EBITDA down 14% and sales up 2%.SCL
Q1 20266 May 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation28 Apr 2026 - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing25 Mar 2026 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 20242 Feb 2026 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 202417 Jan 2026 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 202524 Dec 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 202423 Dec 2025 - Key votes include director elections, executive pay, auditor ratification, and equity plan expansion.SCL
Proxy Filing1 Dec 2025 - Strategic investments and innovation drive growth in key markets, with renewed segment momentum in 2024.SCL
16th Annual Midwest Ideas Conference23 Nov 2025